“Accelerated phase” chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies

Saved in:
Bibliographic Details
Published in:Hematological oncology 2022-10, Vol.40 (4), p.805-808
Main Authors: Lapierre, Léopoldine, Syrykh, Charlotte, Largeaud, Laetitia, Cabarrou, Bastien, Filleron, Thomas, Oberic, Lucie, Kanoun, Salim, Coster, Lucie, Laurent, Camille, Branco, Benoît, Gadaud, Noémie, Récher, Christian, Brechemier, Delphine, Balardy, Laurent, Vergez, François, Ysebaert, Loïc, Gauthier, Martin
Format: Article
Language:English
Subjects:
accelerated phase
BCL2 inhibitor
Chronic lymphocytic leukemia
Health risks
Leukemia
targeted therapies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2985